1.
The future of atrial fibrillation management: integrated care and stratified therapy
by Kirchhof, Paulus, Prof
The Lancet (British edition), 2017, Vol.390 (10105), p.1873-1887
2.
Probing oral anticoagulation in patients with atrial high rate episodes. Rationale and design of the Non vitamin K antagonist Oral anticoagulants in patients with Atrial High rate...
by Kirchhof, Paulus
The American heart journal, 2017, Vol.190, p.12-18
3.
Evolving perspectives for personalised management of patients with atrial fibrillation
by Kirchhof, Paulus
Heart (British Cardiac Society), 2014, Vol.100 (14), p.1071-1072
4.
Can biomarkers balance stroke and bleeding risk?
by Kirchhof, Paulus
The Lancet (British edition), 2016, Vol.387 (10035), p.2266-2268
5.
Efficacy of β blockers in patients with heart failure plus atrial fibrillation: an individual-patient data meta-analysis
by Kotecha, Dipak, Dr
The Lancet (British edition), 2014, Vol.384 (9961), p.2235-2243
6.
Almanac 2015: atrial fibrillation research in Heart
by Jawad-Ul-Qamar, Muhammad
Heart (British Cardiac Society), 2016, Vol.102 (8), p.573-580
7.
Improving outcomes in patients with atrial fibrillation: Rationale and design of the Early treatment of Atrial fibrillation for Stroke prevention Trial
by Kirchhof, Paulus
The American heart journal, 2013, Vol.166 (3), p.442-448
8.
Impact of standardized MONitoring for Detection of Atrial Fibrillation in Ischemic Stroke (MonDAFIS): Rationale and design of a prospective randomized multicenter study
by Haeusler, Karl Georg, MD
The American heart journal, 2015, Vol.172, p.19-25
9.
Short-term versus long-term antiarrhythmic drug treatment after cardioversion of atrial fibrillation (Flec-SL): a prospective, randomised, open-label, blinded endpoint assessment t...
by Kirchhof, Paulus, Prof
The Lancet (British edition), 2012, Vol.380 (9838), p.238-246
10.
Apixaban compared with parenteral heparin and/or vitamin K antagonist in patients with nonvalvular atrial fibrillation undergoing cardioversion: Rationale and design of the EMANATE...
by Ezekowitz, Michael D
The American heart journal, 2016, Vol.179, p.59-68
11.
Brain MRI to personalise atrial fibrillation therapy: current evidence and perspectives
by Haeusler, Karl Georg
Heart, 2014, Vol.100 (18), p.1408-1413
12.
Heartbeat: Highlights from the issue
by Kirchhof, Paulus
Heart (British Cardiac Society), 2014, Vol.100 (11), p.817-818
13.
A proposal for new clinical concepts in the management of atrial fibrillation
by Camm, A. John, MD
The American heart journal, 2012, Vol.164 (3), p.292-302.e1
14.
Rationale and design of the eXplore the efficacy and safety of once-daily oral riVaroxaban for the prEvention of caRdiovascular events in patients with nonvalvular aTrial fibrillat...
by Ezekowitz, Michael D., MD, PhD
The American heart journal, 2014, Vol.167 (5), p.646-652
15.
Frequent and possibly inappropriate use of combination therapy with an oral anticoagulant and antiplatelet agents in patients with atrial fibrillation in Europe
by De Caterina, Raffaele
Heart (British Cardiac Society), 2014, Vol.100 (20), p.1625-1635
16.
Antiarrhythmic drug treatment after cardioversion of atrial fibrillation – Authors' reply
by Kirchhof, Paulus
The Lancet (British edition), 2012, Vol.380 (9852), p.1468-1468
17.
217 Differences in Blood Biomarker Composition Between Paroxysmal AF and Sinus Rhythm Patients, Without Heart Failure
by Tull, Samantha
Heart (British Cardiac Society), 2016, Vol.102 (Suppl 6), p.A143-A144
18.
191 Advancement of Optical Mapping through Automated Algorithms and Second Generation CMOS Detectors to Reveal Murine Atrial Activation Patterns and Regional Variation of Action Po...
by Yu, Ting Yue
Heart (British Cardiac Society), 2014, Vol.100 (Suppl 3), p.A106-A106
19.
Ablation of atrial fibrillation: for whom and how?
by Kirchhof, Paulus
Heart, 2010, Vol.96 (16), p.1325-1330
20.
170 Plakoglobin Deficiency Predisposes to Left Atrial Electrical Remodeling Following Chronic Exposure to Anabolic Steroids
by Holmes, Andrew
Heart (British Cardiac Society), 2016, Vol.102 (Suppl 6), p.A119-A119
